Login / Signup

Randomized trials of therapeutic heparin for COVID-19: A meta-analysis.

Michelle SholzbergBruno R da CostaGrace H TangHassan RahhalMusaad AlHamzahLisa Baumann KreuzigerFionnuala Ní ÁinleMozah Obaid AlmarshoodiPaula D JamesDavid LillicrapMarc CarrierAndrew N BeckettMichael FralickSaskia MiddeldorpAgnes Y Y LeeKevin E ThorpeElnara Márcia NegriAndrea N EdgintonPeter Jüninull null
Published in: Research and practice in thrombosis and haemostasis (2021)
= .034). In conclusion, therapeutic heparin is beneficial in moderately ill patients but not in severely ill patients hospitalized with COVID-19.
Keyphrases
  • end stage renal disease
  • coronavirus disease
  • newly diagnosed
  • ejection fraction
  • sars cov
  • chronic kidney disease